The cross-border legal environment

China is the world's second-largest pharma market and an inseparable link in the global innovation chain. Whether a multinational introduces an innovative product into China, a Chinese company takes its own product global, or the two transact through technology licensing — cross-border deals face overlapping regimes: China's drug regulation, technology import/export controls, foreign exchange, cross-border data rules and international anti-bribery law (FCPA/UKBA).

License-in — importing global innovation

License-in is the main route for Chinese companies to access global innovative products. The typical structure: a Chinese company as licensee obtains exclusive rights to develop, register, manufacture and commercialise a drug in Greater China from an overseas pharma/biotech licensor.

Legal due diligence in license-in deals

  • China registration feasibility: registration class, data-gap analysis (does foreign data support a China NDA, or is a Phase III bridging study required?) and timelines.
  • Patent status and risk: China legal status of the target patents, third-party patents and FTO risk, and the impact of patent linkage.
  • HGR assessment: whether the deal involves international cooperation or cross-border transfer of China HGR — and the approval/filing route.
  • Technology import/export controls: whether the technology falls within the prohibited/restricted export catalogues.
  • MAH eligibility: whether the licensee can act as China MAH.

License-out — Chinese innovation going global

Chinese innovators licensing products out to multinationals has grown explosively. Key China-law issues:

  • Technology export licensing/filing: whether licensing patents and know-how abroad requires export permission or filing.
  • HGR data provision: sharing China clinical data triggers HGR information-export filing or security review.
  • Foreign exchange and tax: handling of upfront, milestone and royalty income.
  • Sensitive-technology review: deals involving gene editing or AI drug discovery may require national-security assessment.

Multi-regional clinical trials (MRCT) in China

Multinationals include China in global Phase III MRCTs both to use Chinese patients and investigators and to satisfy China's "Chinese population data" requirement. China-compliance spans several dimensions:

  • China IND and ethics: an MRCT still requires a China IND (or filing) and ethics approval at each site.
  • HGR international-cooperation approval/filing: almost any MRCT touches Chinese data accessed by foreign sponsors/CROs — the question is approval vs. filing.
  • Cross-border data transfer: the central database usually sits abroad; uploading China site data is a data export subject to PIPL and the Data Security Law.
  • Sufficiency of Chinese-subject data: CDE requires the China subgroup's efficacy and safety data to be adequate and to contribute to overall conclusions.

Cross-border data flows — the special pharma challenge

  • Trial data export: China patient data to overseas central databases.
  • Pharmacovigilance data export: China adverse-event reports to global PV databases.
  • Genetic data export (HGR): a doubly-regulated area — HGR rules plus the Data Security Law.
  • Compliance routes: standard contractual clauses (SCC) filing, certification, or security assessment for "important data" export.

Import drug registration

  • Pharmaceutical requirements: complete CMC data and acceptance of overseas on-site GMP inspection.
  • Domestic agent liability: a foreign MAH must appoint a Chinese legal entity as agent, jointly and severally liable with the MAH.
  • Chinese labelling: labels and instructions must be in Chinese and approved by CDE.